Inflammx Therapeutics, Inc. Alternatives & Competitors
12 companies similar to Inflammx Therapeutics, Inc. — Modulation of Inflammasome mediated Autoinflammation - in Ophthalmology, Nephro...
Companies similar to Inflammx Therapeutics, Inc.
Azome Therapeutics
Developing selective NLRP3 inflammasome inhibitors for severe inflammatory diseases
Osprey Pharmaceuticals USA
Pioneering protein therapeutics to combat inflammation and immune diseases with targeted f...
Cell Care Therapeutics
Developing first-in-class stem cell derived biopharmaceuticals to treat inflammatory and d...
Therini Bio, Inc.
A new approach to block vascular-mediated inflammation
Rival Readout
Competing with Inflammx Therapeutics, Inc.? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Nicox
Maintain vision and improve ocular health
Bionure
Clinical stage biotech developing new drugs for CNS diseases.
D-Sight S.L.
Spin-off company from VHIR developing new innovative treatments for neurodegenerative dise...
Inimex Pharmaceuticals
Advancing health by harnessing the body's natural defenses with innovative, non-inflammato...
Proprius Pharmaceuticals
A San Diego innovator specializing in rheumatology and autoimmune care, offering promising...
KalVista Pharmaceuticals, Inc.
Creating a new generation of small molecule protease inhibitors for HAE and DME.
Montis Biosciences
Pioneering next-gen therapeutics to harness C1q's central role in neuroinflammatory diseas...
About Inflammx Therapeutics, Inc.
Brian Levy is a clinical stage company founded in 2005 and headquartered in the United States. The company focuses on developing an orally administered compound to inhibit the dysregulated NLRP3 Inflammasome pathway of autoinflammation. Their Phase 2 asset, Xiflam, is set to undergo clinical trials in 2022 for indicati...
Biopharmaceuticals, Ophthalmology, Nephropathy, Neurodegenerative Diseases, Clinical Stage Company, Drug Development, Inflammation, Autoinflammation, NLRP3 Inflammasome Pathway, Diabetic Macular Edema, Diabetic Retinopathy, Gap Junction Channel Modulation, Drug Candidates, Therapeutics Development, San Diego
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Inflammx Therapeutics, Inc.: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Inflammx Therapeutics, Inc. on 14 Sep 2024. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.